Your session is about to expire
← Back to Search
Flibanserin for Prostate Cancer (RAD 2003 Trial)
RAD 2003 Trial Summary
This trial is testing whether flibanserin, a drug typically used to treat low sexual interest in women, can promote sexual interest in men with prostate cancer who are receiving androgen suppression (a treatment that lowers testosterone levels). The trial is double-blinded, meaning that neither the participants nor the researchers will know who is receiving the drug and who is receiving the placebo until the trial is over.
RAD 2003 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRAD 2003 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RAD 2003 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have experienced a decrease in my sexual interest.I am currently on hormone therapy for my condition.I am not planning to receive any cancer treatments other than the study.I can take pills and will follow the study plan.You have tried to have sex.Before hormone therapy, I had erection issues not solved by medications like Viagra.I am experiencing symptoms due to my active prostate cancer.I was sexually active within the last 6 months before starting hormone therapy.I am currently taking a medication that is a monoamine oxidase inhibitor.I am not on prostate cancer treatment other than hormone therapy or abiraterone.You drink more than 2 alcoholic drinks every day.I currently have a sexual partner.I am not taking any strong or moderate drugs that affect liver enzymes.I am a man older than 18.My prostate cancer diagnosis was confirmed through a tissue examination.I do not have symptoms from my prostate cancer spreading.
- Group 1: Placebo + ADT
- Group 2: Flibanserin + ADT
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you provide an overview of the previous studies utilizing Androgen deprivation therapy?
"Currently, two clinical studies are in progress concerning Androgen deprivation therapy. Neither of the active investigations is at Phase 3 yet; however, most trials dedicated to this treatment take place in Houston Texas with a couple other sites conducting research as well."
Has there ever been a similar experiment to this one before?
"Androgen deprivation therapy has been studied since the beginning of 2020, when Sprout Pharmaceuticals initially sponsored a clinical trial involving 60 participants. After gaining Phase 2 drug approval following this first research effort, two new active studies are now being conducted across two cities in one country."
What is the current enrolment count for this clinical experiment?
"Affirmative. According to clinicaltrials.gov, the trial was first posted on July 2nd 2021 and has since been updated as recently as July 20th 2022. At present, 50 patients are being sought by a single medical facility."
Is enrollment in this trial available to qualified individuals?
"As per the information on clinicaltrials.gov, this research is in the process of enrolling participants. The trial was initially announced on July 2nd 2021 and went under its most recent update on July 20th 2022."
To what extent can Androgen deprivation therapy be detrimental to individuals?
"Our team at Power has tallied the safety of Androgen deprivation therapy as a 2, since there is evidence for its safety but none yet for efficacy due to this being a Phase 2 trial."
Share this study with friends
Copy Link
Messenger